key: cord-0772706-ilnopzi0 authors: Wang, Pengfei; Liu, Lihong; Nair, Manoj S.; Yin, Michael T.; Luo, Yang; Wang, Qian; Yuan, Ting; Mori, Kanako; Solis, Axel Guzman; Yamashita, Masahiro; Garg, Ankur; Purpura, Lawrence J.; Laracy, Justin C.; Yu, Jian; Joshua-Tor, Leemor; Sodroski, Joseph; Huang, Yaoxing; Ho, David D. title: SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease date: 2020-09-25 journal: Emerging microbes & infections DOI: 10.1080/22221751.2020.1823890 sha: c60f19c7184f3d8ec5c467615e82a588b6a3ad82 doc_id: 772706 cord_uid: ilnopzi0 We studied plasma antibody responses of 35 patients about 1 month after SARS-CoV-2 infection. Titers of antibodies binding to the viral nucleocapsid and spike proteins were significantly higher in patients with severe disease. Likewise, mean antibody neutralization titers against SARS-CoV-2 pseudovirus and live virus were higher in the sicker patients, by ∼5-fold and ∼7-fold, respectively. These findings have important implications for those pursuing plasma therapy, isolation of neutralizing monoclonal antibodies, and determinants of immunity. The coronavirus disease 2019 (COVID-19) is an infection caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Together with SARS-CoV, which caused an outbreak 17 years ago, SARS-CoV-2 is a member of the subgenus Sarbecovirus. Both viruses express a glycoprotein termed spike protein (S), which mediates viral entry into ACE2-positive host cells and is therefore the target of virus-neutralizing antibodies [1] . Another structural protein is the nucleocapsid protein (NP), which is the most abundant and highly immunogenic protein in coronaviruses, making it a suitable candidate for diagnostic assays [2] . A study of antibody responses to SARS-CoV-2 in patients with COVID-19 showed that nearly all patients developed virus-specific antibodies within 2-3 weeks after symptom onset [3] . Most serologic studies [3] [4] [5] largely focused on binding antibodies to S and NP, but not virus-neutralizing antibodies even though such antibodies can be used therapeutically or prophylactically. Infusion of convalescent plasma has been used to treat SARS-CoV-2 [6] . The measurement of neutralizing antibodies is critical in finding the best donors for plasma therapy, as well as being the gold standard to evaluate vaccine responses. Recent vaccine and re-infection studies in non-human primates suggest that neutralizing antibodies are the correlate of protection against SARS-CoV-2 [7, 8] . Studies using convalescent plasma to treat SARS-CoV-2 infections were performed only on a limited number of patients, and there were no careful measurements of neutralizing antibody titers to correlate with the clinical outcome [9] . This study examines SARS-CoV-2 neutralizing antibodies in the plasma of patients with different disease severity. We studied 35 patients seen at Columbia University Irving Medical Center with PCR-confirmed SARS-CoV-2 infection to assess their plasma antibody responses to the virus. The age, sex, and time of blood collection after onset of symptoms for each patient are summarized in Supplementary Table 1 . Patients who required hospitalization in the intensive care unit (19) were categorized as Severe, whereas those with milder disease with or without hospitalization (16) were categorized as Non-severe. As expected, Severe cases were older (range 34-84; mean 58)thanNon-severecases(range20-58;mean38).Importantly, blood collection was taken, on average, about one month after the onset of symptoms in both groups. Immunoassays to quantify antibodies to SARS-CoV-2 NP and S trimer were used to measure binding antibody titers in plasma of both Severe and Non-severe patients. Plasma titers of antibodies to SARS-CoV-2 NP and S trimer were substantially higher in Severe patients than in Non-severe patients (Figure 1a) . Specifically, for NP-directed antibodies, the reciprocal plasma titers ranged from 292 to 37,099 (mean 5086) for Severe cases and from 170 to 1376 (mean 615) for Non-severe cases (Figure 1b) . The mean plasma titer was ∼8-fold higher in the Severe group, and this difference was statistically significant (p = 0.036). Similarly, for S trimer-directed antibodies, the reciprocal plasma titers ranged from 257 to 18,397 (mean 2985) for Severe patients and from <100 to 1963 (mean 364) for Nonsevere patients (Figure 1b and Supplementary Table 1 ). The mean plasma titer was also ∼8-fold higher in Lines in (b) and (d ) represent mean ± SEM and p values were calculated by two-tailed t-test. * p < 0.05; *** p < 0.001. In (e-f), the Pearson correlation coefficient (r) and the probability p value were calculated using GraphPad Prism. the Severe group, and this difference was again statistically significant (p = 0.016). Next, antibody neutralization assays against SARS-CoV-2 pseudovirus and live virus (2019-nCoV/ USA_WA1/2020) were performed on plasma samples from Severe and Non-severe patients. Overall, both SARS-CoV-2 pseudovirus and live virus neutralization titers were substantially higher in the plasma of Severe patients compared to those of Non-severe patients (Figure 1c) . Specifically, in the SARS-CoV-2 pseudovirus assay, the reciprocal plasma neutralizing titers ranged from <100 to 13,710 (mean 2545) for Severe cases and from <100 to 1463 (mean 491) for Nonsevere cases (Figure 1d and Supplementary Table 1 ). The mean pseudovirus neutralizing titer was ∼5-fold higher in the Severe group, and this difference was statistically significant (p = 0.015). Similarly, in the SARS-CoV-2 live virus assay, the reciprocal plasma titers ranged from 926 to 30,175 (mean 10,701) for Severe patients and from <100 to 6884 (mean 1485) for Non-severe patients (Figure 1d and Supplementary Table 1 ). The mean live virus neutralizing titer was ∼7-fold higher in the Severe group, and this difference was again statistically significant (p < 0.001). A few other findings were notable. First, the plasma neutralizing titers against the SARS-CoV-2 pseudovirus correlated quite well with the titers obtained against the live virus (Figure 1e ). In addition, neutralizing titers correlated well with S trimer-binding antibody titers as determined by quantitative immunoassay (Figure 1f) . The results of this study show that patients with severe SARS-CoV-2 disease have more robust binding antibodies to both NP and S trimer (Figure 1a,b) . Functionally active antibodies capable of virus neutralization were also moreabundantinthesickerpatients(Figure1c,d).Thelatter finding is reminiscent of the observation that HIV-1 broadly neutralizing antibodies were most commonly found in patients with persistent viremia for a protracted period [10] . There is evidence that patients with severe SARS-CoV-2 infection have a higher viral load [5] , and perhaps a longer exposure to a greater abundance of viral antigens is the basis for our findings. Regardless, theresultsreportedhereindohaveimportantimplications for donor selection when pursuing plasma therapy or isolating neutralizing monoclonal antibodies. Of course, this selection is best made by assessing virus-neutralizing activity in the serum or plasma of potential donors. However, even an S trimer-based immunoassay could provide useful guidance in choosing convalescent patients who have the most robust neutralizing antibodies (Figure 1f ). The scientific community and general public eagerly awaitdatathatcouldanswerwhetherhavingvirus-neutralizing antibodies is equivalent to having protective immunity. The strong correlations observed here between antibodies that bind the S trimer and antibodies that neutralize the virus could facilitate future studies to understand what constitutes immunity against SARS-CoV-2. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses Antibody responses to SARS-CoV-2 in patients with COVID-19 Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Effectiveness of convalescent plasma therapy in severe COVID-19 patients Development of an inactivated vaccine candidate for SARS-CoV-2 DNA vaccine protection against SARS-CoV-2 in rhesus macaques Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma Determinants of HIV-1 broadly neutralizing antibody induction We thank Professor Kwok-yung YUEN, University of Hong Kong and Eldad A. Hod, Columbia University for providing some of the patient samples. No potential conflict of interest was reported by the authors.